199 related articles for article (PubMed ID: 8772594)
21. [TSH secreting adenoma of pituitary gland (TSHom) - rare cause of hyperthyroidism in pregnancy].
Bolz M; Körber S; Schober HC
Dtsch Med Wochenschr; 2013 Feb; 138(8):362-6. PubMed ID: 23404323
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
[TBL] [Abstract][Full Text] [Related]
23. TSH producing pituitary tumor: biochemical diagnosis and long-term medical management with octreotide.
Chayen SD; Gross D; Makhoul O; Glaser B
Horm Metab Res; 1992 Jan; 24(1):34-8. PubMed ID: 1612557
[TBL] [Abstract][Full Text] [Related]
24. A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.
Erem C; Hacihasanoglu A; Sari A; Onder Ersöz H; Ukinç K; Fidan S
Endocrine; 2004 Nov; 25(2):141-5. PubMed ID: 15711028
[TBL] [Abstract][Full Text] [Related]
25. Thyrotropin-secreting pituitary tumor and Hashimoto's disease: a novel association.
Iskandar SB; Supit E; Jordan RM; Peiris AN
South Med J; 2003 Sep; 96(9):933-6. PubMed ID: 14513996
[TBL] [Abstract][Full Text] [Related]
26. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM
Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
[TBL] [Abstract][Full Text] [Related]
27. A thyrotropin-secreting macroadenoma with positive growth hormone and prolactin immunostaining: A case report and literature review.
Kuzu F; Bayraktaroğlu T; Zor F; G N BD; Salihoğlu YS; Kalaycı M
Niger J Clin Pract; 2015; 18(5):693-7. PubMed ID: 26096253
[TBL] [Abstract][Full Text] [Related]
28. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism.
Mannavola D; Persani L; Vannucchi G; Zanardelli M; Fugazzola L; Verga U; Facchetti M; Beck-Peccoz P
Clin Endocrinol (Oxf); 2005 Feb; 62(2):176-81. PubMed ID: 15670193
[TBL] [Abstract][Full Text] [Related]
29. Thyrotropin secreting pituitary adenoma effectively treated with octreotide.
Fukuda T; Yokoyama N; Tamai M; Imaizumi M; Kimura H; Tominaga T; Ashizawa K; Kiriyama T; Yoshimine H; Ohishi K; Eguchi K
Intern Med; 1998 Dec; 37(12):1027-30. PubMed ID: 9932634
[TBL] [Abstract][Full Text] [Related]
30. Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors.
Katznelson L; Oppenheim DS; Coughlin JF; Kliman B; Schoenfeld DA; Klibanski A
J Clin Endocrinol Metab; 1992 Nov; 75(5):1318-25. PubMed ID: 1358910
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
Zhang CF; Liang D; Zhong LY
Chin Med J (Engl); 2012 Aug; 125(15):2758-63. PubMed ID: 22931988
[TBL] [Abstract][Full Text] [Related]
32. [Octreotide in the treatment of thyrotropin-secreting pituitary adenomas].
Podoba J; Hnilica P; Makaiová I; Kovácová S; Rybár M; Gecík K; Belan V; Steno J
Vnitr Lek; 1997 Sep; 43(9):607-10. PubMed ID: 9750471
[TBL] [Abstract][Full Text] [Related]
33. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
[TBL] [Abstract][Full Text] [Related]
34. [New elements in the diagnosis and treatment of thyrotropic pituitary adenomas with hyperthyroidism].
Linquette M; Cappoen JP; Mazzuca M
Bull Acad Natl Med; 1989 Feb; 173(2):217-20; discussion 221-2. PubMed ID: 2765997
[TBL] [Abstract][Full Text] [Related]
35. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
de Bruin TW; Kwekkeboom DJ; Van't Verlaat JW; Reubi JC; Krenning EP; Lamberts SW; Croughs RJ
J Clin Endocrinol Metab; 1992 Nov; 75(5):1310-7. PubMed ID: 1430093
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
37. [Effect of long-term treatment with octreotide-lar in a TSH-secreting pituitary macroadenoma and secondary hyperthyroidism].
Del Monte P; Bernasconi D; Ruelle A; Marugo A; Marugo M; Torre R
Minerva Endocrinol; 2005 Jun; 30(2):95-9. PubMed ID: 15988405
[TBL] [Abstract][Full Text] [Related]
38. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.
Chanson P; Weintraub BD; Harris AG
Ann Intern Med; 1993 Aug; 119(3):236-40. PubMed ID: 8323093
[TBL] [Abstract][Full Text] [Related]
39. A thyrotropin-secreting pituitary adenoma as a cause of thyrotoxic periodic paralysis.
Alings AM; Fliers E; de Herder WW; Hofland LJ; Sluiter HE; Links TP; van der Hoeven JH; Wiersinga WM
J Endocrinol Invest; 1998 Nov; 21(10):703-6. PubMed ID: 9854688
[TBL] [Abstract][Full Text] [Related]
40. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
